Sinopia Biosciences
The AI engine Fit Assessment
BetaSinopia Biosciences effectively leverages machine learning and multi-omics data to discover new patterns and expand therapeutic options, optimizing the drug discovery process.
Blurb
Sinopia Biosciences enables data-driven drug discovery by means of multi-omics data, machine learning, network analyses, and disease models.
HQ Location
San Diego (United States)
Founded
2014
Employees
1 - 10
Total funding raised
$16.61M
Last Funding Event
Grant, $2.20M, September 12, 2024
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Drug Discovery Optimization
Developer of a data-driven drug discovery platform designed to identify and advance novel therapeutics. The company's platform integrates high-throughput screening, multi-omics data, artificial intelligence, and network analysis to identify novel targets and mechanisms of disease, enabling researchers to study diseases and potential drugs in greater detail, which can lead to the development of new treatments.